CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
CTS Charlotte Lab successfully implemented WNV NAT testing on the Panther Testing Platform on Monday...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
We received an updated WNV package insert; please note the manufacturer and license number has been ...